Cassava, without admitting or denying the SEC’s allegations, agreed to pay a monetary penalty of $40 million. The Company cooperated fully with the SEC’s investigation and has implemented remedial ...
MeridianLink announced an underwritten secondary public offering of 6 million shares by funds managed by Thoma Bravo. The selling stockholders plan to grant the underwriter an option to purchase up to ...
AUSTIN, Texas, Sept. 24, 2024 (GLOBE NEWSWIRE) -- CassavaSciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced the Claude Nicaise, M.D ...
Discover how Cassava Sciences Inc. secures a patent for innovative pharmaceutical compositions using crystalline and amorphous polymorphs, enhancing therapeutic efficacy.
Results that may be inaccessible to you are currently showing.